Editorial: risk of loss of response to anti-TNFα agents in patients with inflammatory bowel disease-the longer the less?

被引：0
|
作者：
Goren, Idan [1 ,2 ]
Yanai, Henit [1 ,2 ]
机构：
[1] Rabin Med Ctr, Div Gastroenterol, IBD Ctr, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2022年 / 55卷 / 02期
关键词：
INFLIXIMAB; DRUG;
D O I：
10.1111/apt.16648
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：244 / 245
页数：2
相关论文
共 50 条
  • [1] Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases - the longer the less? Authors' reply
    Schultheiss, Johannes P. D.
    Mahmoud, Remi
    Fidder, Herma H.
    Oldenburg, Bas
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (02) : 246 - 246
  • [2] Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease
    Schultheiss, Johannes P. D.
    Mahmoud, Remi
    Louwers, Jonas M.
    van der Kaaij, Michiel T.
    van Hellemondt, Boris P.
    van Boeckel, Petra G.
    Mahmmod, Nofel
    Jharap, Bindia
    Fidder, Herma H.
    Oldenburg, Bas
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (10) : 1298 - 1308
  • [3] Factors Predicting Response to Anti-TNF Agents for Patients With Inflammatory Bowel Disease
    Yoon, Soon Man
    Haritunians, Talin
    Chhina, Sultan
    Ye, Byong Duk
    Shih, David Q.
    Vasiliauskas, Eric
    Ippoliti, Andrew
    Targan, Stephan
    Melmed, Gil Y.
    McGovern, Dermot
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S49 - S50
  • [4] Letter: loss of response to anti-TNFα agents in patients with inflammatory bowel disease depends on treatment duration
    Ben-Horin, Shomron
    Ungar, Bella
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (04) : 497 - 498
  • [5] Loss of response to anti-TNF in inflammatory bowel disease in a Portuguese centre
    Sousa, M.
    Silva, A. P.
    Rodrigues, A.
    Rodrigues, J.
    Silva, J.
    Gomes, C.
    Proenca, L.
    Carvalho, J.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S313 - S314
  • [6] Familial Aggregation in the Response to Anti-TNF in Inflammatory Bowel Disease Patients
    Billiet, Thomas
    Cleynen, Isabelle
    Ballet, Vera
    Ferrante, Marc
    Van Steen, Kristel
    Rutgeerts, Paul J.
    Vermeire, Severine
    [J]. GASTROENTEROLOGY, 2013, 144 (05) : S647 - S647
  • [7] PARADOXICAL INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH SPONDYLOARTHROPATHIES TREATED WITH ANTI-TNF AGENTS
    Ancuta, C.
    Pomirleanu, C.
    Paiu, R.
    Ancuta, E.
    Chirieac, R.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (01) : S66 - S66
  • [8] Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents
    Guerra, Ivan
    Gisbert, Javier P.
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2013, 7 (01) : 41 - 48
  • [9] Letter: loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply
    Mahmoud, Remi
    Schultheiss, Johannes P. D.
    Fidder, Herma H.
    Oldenburg, Bas
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (04) : 499 - 500
  • [10] Noncanonical NF-κB Signaling Upregulation in Inflammatory Bowel Disease Patients is Associated With Loss of Response to Anti-TNF Agents
    Nguyen, Vu Q.
    Eden, Kristin
    Morrison, Holly A.
    Sammons, Megan B.
    Knight, Kristin K.
    Sorrentino, Siena
    Brock, Rebecca M.
    Grider, Douglas J.
    Allen, Irving C.
    Sorrentino, Dario
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
12345